Clinical Trial Update: Carboplatin and Bevacizumab for Recurrent Ependymoma [Phase 2]

View source ↗

Summary

Phase 2 trial of carboplatin plus bevacizumab for recurrent ependymoma has completed, and results have been posted. The study evaluated efficacy and safety in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Ependymoma
• Ependymoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Ependymoma, Anaplastic Ependymoma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-28